ArticleBiomedicines2022
Prognostic Role of Systemic Inflammatory Markers in Patients Undergoing Surgical Resection for Oral Squamous Cell Carcinoma.
Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 7 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Preoperative Inflammatory Blood Indices as Prognostic Markers in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Inflammation-driven carcinogenesis in oral cancer: A systematic review of cellular mechanisms and clinical perspectives.The Indian journal of medical research · 2026Pooled it
- Prognostic Significance of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Tumor-Associated Neutrophils in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Pooled it
- Hematological parameters as predictors of oral cancer prognosis: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2025Pooled it
- Prognostic value of systemic immune-inflammation index and systemic inflammation response index for oral cancers: A systematic review and meta-analysis.Medicina oral, patologia oral y cirugia bucal · 2024Pooled it
- Prognostic value of platelet-to-lymphocyte ratio in patients with oral squamous cell carcinoma: a systematic review and meta-analysis.BMC oral health · 2024Pooled it
- Prognostic and clinicopathological role of pretreatment systemic immune-inflammation index in patients with oral squamous cell carcinoma: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Time-dependent prognostic value of perioperative changes in the systemic inflammation response index for overall survival in oral tongue squamous cell carcinoma: a retrospective cohort study.Clinical oral investigations · 2026Article
- Prognostic Value of Pre-Treatment Systemic Inflammatory Markers in Pediatric Unilateral Wilms Tumor.Cancers · 2026Article
- Systemic Inflammation, Tumor Isotopic Signatures, and Prognosis in Oral Squamous Cell Carcinoma: Exploratory Integration of Blood- and Tissue-Derived Biomarkers-An Exploratory Retrospective Secondary Analysis.Journal of clinical medicine · 2026Article
- Clinical Significance of Neutrophil-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio in Oral Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Longitudinal Assessment of Hematologic and Immunonutritional Biomarkers from Treatment Initiation to Progression in Metastatic Colorectal Cancer.Biomedicines · 2026Article
- A study on the correlation between systemic inflammatory markers in the local tumor immune microenvironment and Porphyromonas gingivalis infection status in patients with oral squamous cell carcinoma.Frontiers in oncology · 2026Article
- Microenvironment-based immunotherapy in oral cancer: a comprehensive review.Medical oncology (Northwood, London, England) · 2025Review
- Development of a Prognostic Nomogram Incorporating the Naples Prognostic Score for Postoperative Oral Squamous Cell Carcinoma Patients.Journal of inflammation research · 2025Article
- Combined CA125, NSE, and multiple inflammatory indices for diagnosis of oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- Systemic Immune-Inflammatory Index and Other Inflammatory Marker Variations in Oral Squamous Cell Carcinoma Management.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- Novel prognostic nomograms for postoperative patients with oral cavity squamous cell carcinoma in the central region of China.BMC cancer · 2024Article
- Correlation of Prognostic Nutritional Index and Systemic Immune-Inflammation Index with the Recurrence and Prognosis in Oral Squamous Cell Carcinoma with the Stage of III/IV.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Background: A high platelet−lymphocyte ratio (PLR) is a marker of systemic inflammation and, together with the neutrophil−lymphocyte ratio (NLR), is associated with poor outcomes in several cancers. We investigated the prognostic value of PLR and other systemic inflammatory markers, such as NLR, systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), in oral squamous cell carcinoma (OSCC) patients undergoing surgical resection. Methods: We derived PLR, NLR, SII, and SIRI from a retrospective chart review of 269 consecutive OSCC patients. The complete blood count examined in the immediate preoperative period was used to compute PLR, NLR, SII, and SIRI. We analyzed the relationship between these systemic inflammatory markers and the clinicopathologic characteristics, disease-specific survival (DSS), and progression-free survival (PFS) of patients. Results: In the univariate analysis, high PLR and SII were significantly associated with worse DSS and PFS (all p < 0.05). In the multivariate analysis, PLR (HR 2.36, 95% CI 1.28−4.36 for DSS; HR 1.80, 95% CI 1.06−3.06 for PFS) was an independent predictor of survival outcomes. When PLR was analyzed as a continuous variable, the relationship between the outcome and preoperative PLR was not monotonically linear. In the subgroup analysis, PLR was more strongly associated with DSS and PFS in patients who were male, had stage III/IV OSCC, or had lymph node metastasis. Conclusion: Our data suggest that in OSCC patients, the pretreatment PLR is an independent predictor of DSS and PFS. The PLR is a readily available biomarker that will improve prognostication and risk stratification in OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.